Avoiding and managing bleeding complications in patients with non-st-segment elevation acute coronary syndromes

Angiology

Volumn 60, Issue 2, 2009, Pages 148-158

  Potsis, Thomas Z ^a   Katsouras, Christos ^a   Goudevenos, John A ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Acute coronary syndromes; Antithrombotic treatment; Bleeding; Complications

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; NADROPARIN; PLACEBO; REVIPARIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; OPTIMAL DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ELECTROCARDIOGRAPHY; FACTOR X; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HEMORRHAGE; HUMANS; MYOCARDIAL REVASCULARIZATION; POLYSACCHARIDES; PROGNOSIS; RISK FACTORS;

EID: 65249113213     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708317339     Document Type: Review

References (56)

1. Theroux P., Willerson JT, Amstrong PW Progress in treatment of acute coronary syndromes: a 50-year perspective. Circulation. 2000 ; 102: IV2 - IV13.
2. Bassand JP, Hamm CW, Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 ; 28: 1598-660. (Pubitemid 350305871)
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007 ; 50: 652-726.
4. Lincoff AM, Bittl JA, Harrington RA, et al. for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 ; 289: 853-863.
5. Stone GW, McLaurin BT, Cox DA, et al. for the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006 ; 355: 2203-2216.
6. The OASIS 5 Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 ; 354: 1464-1476.
7. Rao SV, O'Grady K., Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 ; 47: 809-816. (Pubitemid 43243106)
8. Rao SV, Eikelboom JW, Granger CB, Harrington RA, Califf RM, Bassand JP Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 ; 28: 1193-1204. (Pubitemid 47343833)
9. Eikelboom JW, Mentha SR, Anand SS, Xie C., Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006 ; 14: 774-782. (Pubitemid 44268228)
10. Cannon CP, Battler A., Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on clinical data standards. J Am Coll Cardiol. 2001 ; 38: 2114-2130. (Pubitemid 33116592)
11. The GUSTO I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993 ; 329: 673-682.
12. Chesebro JH, Knatterud G., Roberts R., et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 ; 76: 142-154. (Pubitemid 17093202)
13. Yusuf S., Zhao F., Mehta SR, Chrolavicious S., Tognoni G., Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345: 494-502. (Pubitemid 32758501)
14. Montalescot G., White HD, Gallo R., et al. for the STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 ; 355: 1006-1017. (Pubitemid 44343544)
15. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001 ; 358: 1855-1863. (Pubitemid 34008652)
16. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol. 2007 ; 99: 288-290. (Pubitemid 46072771)
17. Topol EJ, Easton D., Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 ; 108: 399. (Pubitemid 36935531)
18. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation. 2003 ; 108: 1682-1687. (Pubitemid 37243654)
19. Steinhubl SR, Berger PB, Tif Mann J., et al. for the CREDO investigators. Early and sustained dual oral therapy following percutaneous coronary intervention JAMA. 2002 ; 288: 2411-2420.
20. Lewis BS, Mehta SR, Fox KAA, et al. for the CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Am Heart J. 2005 ; 150: 1177-84. (Pubitemid 41773519)
21. Mehta SR, Yusuf S., Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358: 527-533. (Pubitemid 32772726)
22. Fox KA, Mehta SR, Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation. 2004 ; 110: 1202-1208. (Pubitemid 39202333)
23. Eikelboom JW, Anand SS, Malmberg K., Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000 ; 355: 1936-1942. (Pubitemid 30326097)
24. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation. 2005 ; 112: 3855-3867. (Pubitemid 43739483)
25. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006 ; 354: 1477-1488.
26. Yusuf S., Mehta SR, Xie C., et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA. 2005 ; 293: 427-435.
27. Antman EM, Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Qwave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 1999 ; 100. (Pubitemid 29477268)
28. Yusuf S., Mehta SR, Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 ; 354: 1464-1476.
29. The SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004 ; 292: 45-54. (Pubitemid 38923793)
30. Petersen JL, Mahaffey KW, Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 ; 292: 89-96. (Pubitemid 38923799)
31. Cohen M., Theroux P., Borzak S., et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin. Am Heart J. 2002 ; 144: 470-477.
32. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 ; 146: 628-634. (Pubitemid 37281706)
33. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994 ; 343: 881-886. (Pubitemid 24113631)
34. Boersma E., Harrigton RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet. 2002 ; 359: 189-198. (Pubitemid 34113814)
35. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005 ; 294: 3108-3116. (Pubitemid 43016802)
36. Eagle KA, Gore JM, Anderson FA, et al. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (GRACE). Am J Cardiol. 2005 ; 96: 917-921.
37. Kastrati A., Mehilli J., Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 ; 295: 1531-1538.
38. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001 ; 344: 1888-1894. (Pubitemid 32553357)
39. de Winter RJ, Windhausen F., Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005 ; 353: 1095-1104. (Pubitemid 41317432)
40. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998 ; 338: 1498-1505. (Pubitemid 28226277)
41. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996 ; 335: 775-782.
42. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998 ; 339: 436-443.
43. The PARAGON B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002 ; 105: 316 321.
44. Eikelboom JW, Mentha SR, Anand SS, Xie C., Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006 ; 114: 774-782. (Pubitemid 44268228)
45. Rao SV, O'Grady K., Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005 ; 96: 1200-1206. (Pubitemid 41505393)
46. Yang X., Alexander KP, Chen AY, et al. for the CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE national quality improvement initiative. J Am Coll Cardiol. 2005 ; 46: 1490-1495. (Pubitemid 41446184)
47. Moscucci M., Fox KAA, Cannon CP, et al. for the GRACE Investigators. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J. 2003 ; 24: 1815-1823. (Pubitemid 37280247)
48. Rao SV, Jollis JG, Harrington RA, et al. The relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004 ; 292: 1555-1562. (Pubitemid 39314961)
49. Manoukian SV, Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. An analysis from the ACUITY trial. J Am Coll. 2007 ; 49: 1362-1368. (Pubitemid 46476844)
50. Berkowitz SD, Stinnett S., Cohen M., Fromell GJ, Bigonzi F. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol. 2001 ; 88: 1230-1234. (Pubitemid 33132089)
51. Grace Investigators. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003 ; 89: 1003-1008. (Pubitemid 37046830)
52. Fox KAA, Bassand JP, Mehta SR, et al. on behalf of the OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007 ; 147: 304-310.
53. Serebruany VL, Oshrine BR, Malinin AI, Michelson AD, Ferguson JJ Non-compliance in clinical trials. Am Heart J. 2005 ; 150: 882-886.
54. Wallis JP Nitric oxide and blood: a review. Transfus Med. 2005 ; 15: 1-11. (Pubitemid 40300002)
55. Spiess BD Blood transfusion for cardiopulmonary bypass: the need to answer a basic question. J Cardiothorac Vasc Anesth. 2002 ; 16: 535-538. (Pubitemid 35155263)
56. Agostoni P., Biondi-Zoccai GG, de Benedictis MI, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol. 2004 ; 44: 349-356. (Pubitemid 38950594)